Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Allena Pharmaceuticals, Inc is a biotechnology business based in the US. Allena Pharmaceuticals shares (ALNA) are listed on the NASDAQ and all prices are listed in US Dollars. Allena Pharmaceuticals employs 29 staff and has a market cap (total outstanding shares value) of USD$57.2 million.
|52-week range||USD$0.525 - USD$6.3|
|50-day moving average||USD$1.379|
|200-day moving average||USD$1.5547|
|Wall St. target price||USD$7.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.009|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-57.61%|
|Return on equity TTM||-139.91%|
|Market capitalisation||USD$57.2 million|
TTM: trailing 12 months
There are currently 1.1 million Allena Pharmaceuticals shares held short by investors – that's known as Allena Pharmaceuticals's "short interest". This figure is 15.9% down from 1.3 million last month.
There are a few different ways that this level of interest in shorting Allena Pharmaceuticals shares can be evaluated.
Allena Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Allena Pharmaceuticals shares currently shorted divided by the average quantity of Allena Pharmaceuticals shares traded daily (recently around 2.1 million). Allena Pharmaceuticals's SIR currently stands at 0.51. In other words for every 100,000 Allena Pharmaceuticals shares traded daily on the market, roughly 510 shares are currently held short.
However Allena Pharmaceuticals's short interest can also be evaluated against the total number of Allena Pharmaceuticals shares, or, against the total number of tradable Allena Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Allena Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Allena Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.0345% of the tradable shares (for every 100,000 tradable Allena Pharmaceuticals shares, roughly 35 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Allena Pharmaceuticals.
Find out more about how you can short Allena Pharmaceuticals stock.
We're not expecting Allena Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Allena Pharmaceuticals's shares have ranged in value from as little as $0.525 up to $6.3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Allena Pharmaceuticals's is 2.5477. This would suggest that Allena Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is headquartered in Newton, Massachusetts.
Everything we know about the WorldRemit IPO, plus information on how to buy in.
Everything we know about the Jowell Global IPO, plus information on how to buy in.
Steps to owning and managing AIRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing ACER, with 24-hour and historical pricing before you buy.
Steps to owning and managing WST, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRNA, with 24-hour and historical pricing before you buy.
Steps to owning and managing OLED, with 24-hour and historical pricing before you buy.
Steps to owning and managing RARE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TRVI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.